Cargando…

Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

The combination chemotherapy regimen of eribulin (ERI) and trastuzumab (TRA)—the ERI-TRA regimen—has been shown to be highly tolerable for patients with recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, no sufficient clinical evidence is availab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeki, Toshiaki, Araki, Kazuhiro, Shimada, Ken, Shigekawa, Takashi, Nakayama, Hirofumi, Segawa, Yoshihiko, Mukai, Hirofumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498262/ https://www.ncbi.nlm.nih.gov/pubmed/31149450 http://dx.doi.org/10.1007/s13691-016-0253-y

Ejemplares similares

Phase 1 combination study of Eribulin mesylate with trastuzumab for advanced or recurrent human epidermal growth factor receptor 2 positive breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2014)

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
por: Mukai, Hirofumi, et al.
Publicado: (2016)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab
por: Ueda, Shigeto, et al.
Publicado: (2016)

Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel
por: Araki, Kazuhiro, et al.
Publicado: (2018)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
por: Watanabe, Junichiro, et al.
Publicado: (2017)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
por: Inoue, Kenichi, et al.
Publicado: (2019)

Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety
por: Sugitani, Ikuko, et al.
Publicado: (2017)

Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: Miyahara, Kana, et al.
Publicado: (2022)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
por: Pivot, X., et al.
Publicado: (2016)

Induction of Growth Factor‐receptor and Metalloproteinase Genes by Epidermal Growth Factor and/or Transforming Growth Factor‐α in Human Gastric Carcinoma Cell Line MKN‐28
por: Yoshida, Kazuhiro, et al.
Publicado: (1990)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Pathological complete response of HER2-positive breast cancer to trastuzumab and chemotherapy can be predicted by HSD17B4 methylation
por: Fujii, Satoshi, et al.
Publicado: (2017)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
por: Puhalla, Shannon, et al.
Publicado: (2016)

Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
por: Kashiwagi, Shinichiro, et al.
Publicado: (2017)

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
por: Inoue, Kenichi, et al.
Publicado: (2020)

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2015)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer
por: Dai, Wei Fang, et al.
Publicado: (2022)

Optical Imaging for Monitoring Tumor Oxygenation Response after Initiation of Single-Agent Bevacizumab followed by Cytotoxic Chemotherapy in Breast Cancer Patients
por: Ueda, Shigeto, et al.
Publicado: (2014)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma(†)
por: Kawai, Akira, et al.
Publicado: (2017)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
por: Ohtani, Shoichiro, et al.
Publicado: (2018)

Trastuzumab-Based Combination Chemotherapy in Patients with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Carcinoma ex Pleomorphic Adenoma
por: Arihara, Yohei, et al.
Publicado: (2018)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
por: Satomi-Tsushita, Natsuko, et al.
Publicado: (2019)

Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models
por: Ito, Ken, et al.
Publicado: (2017)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility study
por: Shigekawa, Takashi, et al.
Publicado: (2015)

High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
por: Miyoshi, Yasuo, et al.
Publicado: (2020)

Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience
por: Lutrino, Eufemia S., et al.
Publicado: (2019)

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience
por: Srinivasa, BJ, et al.
Publicado: (2018)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_23hd3epvcuqgp3sefdallcq3n3